BioSpecifics Technologies Corp. is a biopharmaceutical company that originated and continues to develop, in collaboration with Endo Pharmaceuticals, a specific collagenase formulation, collagenase clostridium histolyticum (CCH). The product was first approved by the FDA in 2010 for the treatment of Dupuytren’s contracture and was subsequently approved in 2013 for the treatment of Peyronie’s disease. CCH-aaes was approved by the FDA for a third indication, cellulite, in July 2020. CCH was licensed to Auxilium Pharmaceuticals, Inc. (subsequently acquired by Endo Pharmaceuticals) in 2004 and is currently marketed under the brand name XIAFLEX® in the U.S. We continue to investigate a number of potential future indications for XIAFLEX®.